ZURICH, Jan 7 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) said on Friday the European Commission has approved broader application of its Lucentis drug to treat visually impaired patients, giving sales of the drug a potential boost.
ZURICH, Jan 7 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX) said on Friday the European Commission has approved broader application of its Lucentis drug to treat visually impaired patients, giving sales of the drug a potential boost.
